NENina Egger

Nina Egger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nina Egger has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Konnopka

    Department of Health Economics and Health Services Research, Hamburg Center for Health Economics (HCHE), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Bernhard Strauss

    Institute of Psychosocial Medicine and Psychotherapy, University Hospital Jena, Jena, Germany

    2 shared publications
  • Eric Leibing

    Department of Psychosomatic Medicine and Psychotherapy, University Medicine, Georg-August-University, Goettingen, Germany

    2 shared publications
  • Falk Leichsenring

    Clinic of Psychosomatics and Psychotherapy, Justus-Liebig-University Giessen, Giessen, Germany

    2 shared publications
  • Hans-Helmut König

    Department of Health Economics and Health Services Research, Hamburg Center for Health Economics (HCHE), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications
  • Hans-Helmut König

    Department of Health Economics and Health Service Research, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

    2 shared publications

Latest Publications

  • Cost-utility of a specific collaborative group intervention for patients with functional somatic syndromes

    by Alexander Konnopka, Hans-Helmut König, Claudia Kaufmann, Nina Egger, Beate Wild, Joachim Szecsenyi, Wolfgang Herzog, Dieter Schellberg, Rainer Schaefert


  • Long-term cost-effectiveness of cognitive behavioral therapy versus psychodynamic therapy in social anxiety disorder

    by Nina Egger, Alexander Konnopka, Manfred E. Beutel, Stephan Herpertz, Wolfgang Hiller, Juergen Hoyer, Simone Salzer, Ulrich Stangier, Bernhard Strauss, Ulrike Willutzki, et al.

    Background To determine the cost‐effectiveness of cognitive behavioral therapy (CBT) versus psychodynamic therapy (PDT) in the treatment of social anxiety disorder after a follow‐up of 30 months from a societal perspective. Methods This analysis was conducted alongside the multicenter SOPHO‐NET trial; adults with a primary diagnosis of social anxiety disorder received CBT (n = 209) or PDT (n = 207). Data on health care utilization and productivity loss were collected at baseline, after 6 months (posttreatment), and three further follow‐ups to calculate direct and indirect costs. Anxiety‐free days (AFDs) calculated based on remission and response were used as measure of effect. The incremental cost‐effectiveness ratio (ICER) was determined. Net benefit regressions, adjusted for comorbidities and baseline differences, were applied to derive cost‐effectiveness acceptability curves. Results In the descriptive analysis, the unadjusted ICER favored CBT over PDT and the adjusted analysis showed that CBT's cost‐effectiveness relative to PDT depends on the willingness to pay (WTP) per AFD. As baseline costs differed substantially the unadjusted estimates might be deceptive. If additional WTPs for CBT of €0, €10, and €30 were assumed, the probability of CBT being cost‐effective relative to PDT was 65, 83, and 96%. Direct costs increased compared to baseline across groups, whereas indirect costs did not change significantly. Results were sensitive to considered costs. Conclusions If the society is willing to pay ≥€30 per additional AFD, CBT can be considered cost‐effective, relative to PDT, with certainty. To further increase the cost‐effectiveness more knowledge regarding predictors of treatment outcome seems essential.


  • Open Access

    Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial

    by Martin Härter, Anna-Lena Bartsch, Nina Egger, Hans-Helmut König, Levente Kriston, Holger Schulz, Michael Tiemann, Anna Levke Brütt, Angela Buchholz

    Tobacco consumption is a preventable risk factor for chronic disease and complicates the treatment of medical conditions. Therefore, the German health insurance company AOK NORDWEST has developed a collaborative smoking cessation intervention for individuals with cardiovascular disease, chronic obstructive pulmonary disease and heavy smokers, with the aim of reducing tobacco consumption. The objective of the study ENTER is to evaluate the effectiveness of the collaborative smoking cessation intervention and determine its cost-effectiveness. This study is a cluster-randomized controlled trial conducted with 40 medical practices that are being selected from different geographic regions in Germany. Participating medical practices will be randomly allocated to either the intervention or control group. Within the medical practices, a total of 800 patients will be recruited for participation in the study and blinded to group assignment. Patients are included in the study if they are 18 years or older, insured by AOK, heavy smokers (smoke at least 20 cigarettes per day) and/or suffer from chronic obstructive pulmonary disease or cardiovascular disease. Exclusion criteria are patients who are nonsmokers, who have cognitive impairments or who are illiterate. Physicians from medical practices in the intervention group will motivate patients to participate in a smoking cessation program offered by the health insurance, refer them to the program and ask about their program participation. Physicians from medical practices in the control group will provide usual care. Data collection will take place on the date of study inclusion and after 6 and 12 months. The primary outcome is the amount of cigarettes consumed during the past 30 days, 12 months after the initial medical consultation. Secondary outcomes are abstinence from smoking, health-related quality of life and respiratory complaints. Moreover, a process evaluation and health economic analysis will be performed. The results of this study will help to determine whether the collaborative smoking cessation intervention is an effective and feasible way to promote smoking cessation in the primary care setting and provide evidence regarding its cost-effectiveness. German Clinical Trials Register DRKS00006079 . Registered 4 June 2014.


  • Short-term cost-effectiveness of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: Results from the SOPHO-NET trial

    by Nina Egger, Alexander Konnopka, Manfred E. Beutel, Stephan Herpertz, Wolfgang Hiller, Juergen Hoyer, Simone Salzer, Ulrich Stangier, Bernhard Strauss, Ulrike Willutzki, et al.